Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment

被引：0
|
作者：
Roland Heinig
Marc Lambelet
Johannes Nagelschmitz
Abir Alatrach
Atef Halabi
机构：
[1] Bayer AG,
[2] Research & Development,undefined
[3] Pharmaceuticals,undefined
[4] Clinical Sciences,undefined
[5] CHRESTOS Concept GmbH & Co. KG,undefined
[6] CRS Clinical Research Services Kiel GmbH,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2019年 / 44卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：619 / 628
页数：9
相关论文
共 36 条
  • [21] Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies
    Lentini, Silvia
    Heinig, Roland
    Kimmeskamp-Kirschbaum, Nina
    Wensing, Georg
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 (02) : 172 - 184
  • [22] Pharmacokinetics of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, in Patients With Moderate Hepatic Impairment
    Wang, Ying-Hong
    Liu, Fang
    Luk, Julie Ann Mabalot
    Nirula, Ajay
    Johnson-Levonas, Amy O.
    Lasseter, Kenneth C.
    Marbury, Thomas C.
    Lunde, N. Martin
    Wagner, John A.
    Lai, Eseng
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (03): : 406 - 412
  • [23] Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activityof Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
    Lefebvre, E.
    Gottwald, M.
    Lasseter, K.
    Chang, W.
    Willett, M.
    Smith, P. F.
    Somasunderam, A.
    Utay, N. S.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2016, 9 (03): : 139 - 148
  • [24] Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
    Magda S. C. Fontes
    Jasper Dingemanse
    Atef Halabi
    Monika Tomaszewska-Kiecana
    Patricia N. Sidharta
    Scientific Reports, 12
  • [25] Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
    Fontes, Magda S. C.
    Dingemanse, Jasper
    Halabi, Atef
    Tomaszewska-Kiecana, Monika
    Sidharta, Patricia N.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [26] Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose Ritonavir in Individuals with Mild-to-Moderate Hepatic Impairment
    Sekar, Vanitha
    Spinosa-Guzman, Sabrina
    De Paepe, Els
    Stevens, Tanja
    Tomaka, Frank
    De Pauw, Martine
    Hoetelmans, Richard M. W.
    CLINICAL PHARMACOKINETICS, 2010, 49 (05) : 343 - 350
  • [27] Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose Ritonavir in Individuals with Mild-to-Moderate Hepatic Impairment
    Vanitha Sekar
    Sabrina Spinosa-Guzman
    Els De Paepe
    Tanja Stevens
    Frank Tomaka
    Martine De Pauw
    Richard M. W. Hoetelmans
    Clinical Pharmacokinetics, 2010, 49 : 343 - 350
  • [28] Pharmacokinetics, Efficacy and SAFETY of Lesinurad, a Novel URAT1 Inhibitor, In Individuals with Mild to Moderate Renal Impairment.
    Hagerty, David
    Kerr, Brad
    Shen, Zangong
    Yeh, Li-tain
    Hingorani, Vijay
    Cravets, Matt
    Welp, Jody
    Miner, Jeffrey N.
    Manhard, Kimberly
    Quart, Barry
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S402 - S402
  • [29] The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase
    Khosravan, R
    Grabowski, BA
    Mayer, MD
    Wu, JT
    Joseph-Ridge, N
    Vernillet, L
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (01): : 88 - 102
  • [30] SINGLE-DOSE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST APROCITENTAN IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT.
    Fontes, M.
    Halabi, A.
    Tomaszewska-Kiecana, M.
    Dinge-Manse, J.
    Sidharta, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S47 - S48
1234